Rapport Therapeutics, Inc. (RAPP) has received a new Buy rating, initiated by JMP Securities analyst, Jason Butler.
Jason Butler has given his Buy rating due to a combination of factors that highlight the potential of Rapport Therapeutics, Inc. to deliver significant value. The company is pioneering a novel approach in developing precision therapeutics for central nervous system disorders, utilizing receptor-associated proteins to achieve targeted and selective functions. This method is expected to result in treatments with better safety and tolerability profiles compared to traditional therapies, which is a significant advantage.
Furthermore, Rapport’s lead candidate, RAP-219, has shown promising safety and tolerability in early trials and is currently undergoing a Phase 2a proof-of-concept study for focal epilepsy. The potential market for RAP-219 is substantial, as it targets a significant unmet need among epilepsy patients who do not respond to existing treatments. With a projected peak market penetration and substantial sales potential, along with broader applications for the RAP platform, Butler sees a strong upside in Rapport’s valuation and growth prospects.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RAPP in relation to earlier this year.